Tony Coles, Cerevel Therapeutics CEO
While PhIII Parkinson's trials go slower than expected, Cerevel previews plans to raise $900M
Tony Coles set out to build “the premier neuroscience company” at Cerevel. And that means putting fundraising plans in place well in advance.
Just weeks …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
